XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an update.
XORTX Therapeutics Inc. has submitted a request for a Type C meeting with the FDA to discuss its XRx-026 gout treatment program, aiming to advance its XORLO™ drug formulation toward a New Drug Application (NDA). This move is part of XORTX’s strategy to secure marketing approval in the US, utilizing the FDA’s 505(b)2 development pathway. With the meeting expected within 75 days, XORTX anticipates potentially significant revenue impacts within two years, highlighting the urgent need for alternative gout therapies due to the limitations of current treatments like allopurinol and Febuxostat.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company specializing in innovative therapies for progressive kidney disease and gout. The company focuses on developing proprietary drug formulations, with a particular emphasis on the XRx-026 program for gout treatment, targeting markets in the US and potentially beyond.
YTD Price Performance: -27.71%
Average Trading Volume: 5,023
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$4.18M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.